ImmunoVaccine Inc. (TSE:IMV) insider Pierre Labbé purchased 25,000 shares of the company’s stock in a transaction that occurred on Thursday, July 20th. The shares were bought at an average cost of C$1.22 per share, with a total value of C$30,500.00.
Pierre Labbé also recently made the following trade(s):
- On Friday, July 28th, Pierre Labbé bought 26,825 shares of ImmunoVaccine stock. The stock was purchased at an average price of C$1.22 per share, with a total value of C$32,726.50.
ImmunoVaccine Inc. (TSE IMV) opened at 1.18 on Wednesday. The firm’s 50-day moving average is $1.21 and its 200-day moving average is $1.23. ImmunoVaccine Inc. has a 1-year low of $0.56 and a 1-year high of $1.70. The company’s market capitalization is $141.44 million.
WARNING: This piece of content was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece of content on another website, it was stolen and reposted in violation of United States and international copyright & trademark laws. The correct version of this piece of content can be read at https://stocknewstimes.com/2017/08/16/immunovaccine-inc-tseimv-insider-purchases-c30500-00-in-stock-updated-updated-updated.html.
Separately, National Bank Financial set a C$2.50 price objective on shares of ImmunoVaccine and gave the company an “outperform” rating in a research note on Wednesday, August 9th.
About ImmunoVaccine
Immunovaccine Inc, a clinical stage biopharmaceutical company, develops cancer immunotherapies and infectious disease vaccines based on its DepoVax platform. The companys DepoVax platform is a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system.
Receive News & Ratings for ImmunoVaccine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoVaccine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
